G L Pharma competitive analysis

Loading summary...

Explore patent oppositions filed by G L Pharma against competitors, revealing strategic technology disputes and market positioning.

Last updated on: Oct 23, 2025
Patent NumberTitleApplicantOpposition Date

Get instant updates on new opposition filings by the company

Crush-Resistant Tablets Intended For Preventing Accidental Misuse And Unlawful DiversionETHYPHARMJul 25, 2024
Compositions And Uses For Treating Multiple SclerosisBIOGEN IDEC MAOct 10, 2022
Salts Or Co-Crystals Of 3-(3-Dimethylamino-1-Ethyl-2-Methyl-Propyl)-PhenolGRNENTHALApr 15, 2021
Dosing Regimen For Multiple SclerosisYEDA RESEARCHApr 11, 2019
Low Frequency Glatiramer Acetate TherapyYEDA RESEARCHMar 26, 2019
Break-Resistant Delayed-Release Forms Of AdministrationGRNENTHALDec 19, 2017
Pharmaceutical Preparation Containing Oxycodone And NaloxoneEURO CELTIQUENov 9, 2017
Pharmaceutical Preparation Containing Oxycodone And NaloxoneEURO CELTIQUENov 9, 2017
Low Frequency Glatiramer Acetate TherapyYEDA RESEARCHOct 4, 2017

Latest publications and patents of G L Pharma New

Explore the latest publications and patents granted to G L Pharma, showcasing their recent innovations and technological advancements.

Latest PTAB cases involving G L Pharma

Discover the latest PTAB cases involving G L Pharma, highlighting their recent legal challenges and patent disputes.

Peer Comparison New

IP litigation analysis comparing G L Pharma with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Oct 23, 2025
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
G L PHARMA9 - - -
EURO CELTIQUE - 44 - -
GRNENTHAL - 221 -
YEDA RESEARCH - 21 - 9